MedPath

Upstream Bio, Inc.

๐Ÿ‡บ๐Ÿ‡ธUnited States
Ownership
Holding
Employees
-
Market Cap
-
Website
http://www.upstreambio.com

Clinical Trials

7

Active:2
Completed:3

Trial Phases

2 Phases

Phase 1:2
Phase 2:4

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (6 trials with phase data)โ€ข Click on a phase to view related trials

Phase 2
4 (66.7%)
Phase 1
2 (33.3%)

A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD

Phase 2
Recruiting
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Other: Placebo
First Posted Date
2025-05-20
Last Posted Date
2025-08-01
Lead Sponsor
Upstream Bio Inc.
Target Recruit Count
666
Registration Number
NCT06981078
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Qway Research, LLC, Hialeah, Florida, United States

๐Ÿ‡บ๐Ÿ‡ธ

Velocity Clinical Research, Spartanburg - Pulmonology, Spartanburg, South Carolina, United States

๐Ÿ‡บ๐Ÿ‡ธ

Velocity Clinical Research- Union, Union, South Carolina, United States

and more 6 locations

A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)

Phase 2
Recruiting
Conditions
Severe Asthma
Interventions
Drug: Placebo
First Posted Date
2025-05-11
Last Posted Date
2025-09-19
Lead Sponsor
Upstream Bio Inc.
Target Recruit Count
436
Registration Number
NCT06966479
Locations
๐Ÿ‡บ๐Ÿ‡ธ

California Medical Research Associates Inc., Northridge, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

Allianz Research Institute, Westminster, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

Phoenix Medical Research, Miami, Florida, United States

and more 12 locations

A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)

Phase 2
Active, not recruiting
Conditions
Severe Asthma
Interventions
Drug: Verekitug (UPB-101)
Drug: Placebo
First Posted Date
2024-01-09
Last Posted Date
2025-06-12
Lead Sponsor
Upstream Bio Inc.
Target Recruit Count
479
Registration Number
NCT06196879
Locations
๐Ÿ‡บ๐Ÿ‡ธ

AllerVie Clinical Research, Birmingham, Alabama, United States

๐Ÿ‡บ๐Ÿ‡ธ

Kern Research, Inc., Bakersfield, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

Velocity Clinical Research - Lafayette LA, Los Angeles, California, United States

and more 152 locations

A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Participants With Chronic Rhinosinusitis With Nasal Polyps

Phase 2
Completed
Conditions
Chronic Rhinosinusitis With Nasal Polyps
First Posted Date
2023-12-11
Last Posted Date
2025-08-15
Lead Sponsor
Upstream Bio Inc.
Target Recruit Count
45
Registration Number
2023-508231-31-00
Locations
๐Ÿ‡จ๐Ÿ‡ฟ

ORL ambulance MUDr. Pavel Navratil, Olomouc, Czechia

๐Ÿ‡จ๐Ÿ‡ฟ

Fakultni Nemocnice Hradec Kralove, Novy Hradec Kralove, Czechia

๐Ÿ‡ฉ๐Ÿ‡ช

Universitaetsklinikum Tuebingen AรถR, Tuebingen, Germany

and more 15 locations

Safety and Blood Levels After a Single Injection of UPB-101 in Healthy Japanese and Non-Japanese Non-East Asian Adults

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2022-12-16
Last Posted Date
2023-06-15
Lead Sponsor
Upstream Bio Inc.
Target Recruit Count
32
Registration Number
NCT05653479
Locations
๐Ÿ‡ฌ๐Ÿ‡ง

Richmond Pharmacology, London, United Kingdom

  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

ยฉ 2025 MedPath, Inc. All rights reserved.